Tislelizumab

Tislelizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	PD-1
Clinical data
Other names	BGB-A317[1]; Tisle[2];
ATC code	none;
Identifiers
ChemSpider	none;
UNII	0KVO411B3N;
KEGG	D11487;

Tislelizumab[3][4] (BGB-A317) is a humanized monoclonal antibody directed against PD-1.[5] It prevents PD-1 from binding to the ligands PD-L1 and PD-L2 (hence it is a checkpoint inhibitor). It is being investigated as a treatment for advanced solid tumors.[5]

It is designed to bind less to Fc gamma receptors.[6]

It is being developed by BeiGene and Celgene Corp.[7]

Clinical trials

Phase I trials began in the US and Australia in June 2015 and were expected to complete in mid-2017.[8] Some early results were announced in July 2016.[9][5]

A pivotal phase 2 clinical trial for urothelial cancer started in China in 2017.[6]

It is in a phase 3 trial for NSCLC.[10]

A multicenter phase 3 trial for advanced hepatocellular carcinoma started in Jan 2018.[7]

Pharmacokinetics

Early phase I clinical trial results give an elimination half-life of 11 to 17 days.[5]

References

Lopes, Jose Marques (27 July 2018). "BeiGene's Therapy Candidate Appears to Eliminate Tumors in Half of Hodgkin's Patients in Phase 2 Trial". Lymphoma News Today. Philadelphia, Pennsylvania, United States: BioNews Services.
Erickson, Simon (July 3, 2018). "3 Reasons BeiGene Needs to Be on Your Radar". The Motley Fool. Retrieved 2 Nov 2019.
"tislelizumab (BGB-A317)". BioCentury – BCIQ.
"Investor Overview". BeiGene LTD.
"Meeting Library - Meeting Library". meetinglibrary.asco.org.
"BeiGene (BGNE) Commences Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer".
LTD, BeiGene (2 January 2018). "BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular Carcinoma". GlobeNewswire News Room.
"Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.
"Immunotherapy Trial's Early Results Show Activity in Solid Tumors". 26 July 2016.
"Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Patients With NSCLC - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Lymphoma_News_Today_27Jul2018-1] Lopes, Jose Marques (27 July 2018). "BeiGene's Therapy Candidate Appears to Eliminate Tumors in Half of Hodgkin's Patients in Phase 2 Trial". Lymphoma News Today. Philadelphia, Pennsylvania, United States: BioNews Services.

[Motley_Fool_2018_Erickson-2] Erickson, Simon (July 3, 2018). "3 Reasons BeiGene Needs to Be on Your Radar". The Motley Fool. Retrieved 2 Nov 2019.

[3] "tislelizumab (BGB-A317)". BioCentury – BCIQ.

[4] "Investor Overview". BeiGene LTD.

[ASCO-2016-5] "Meeting Library - Meeting Library". meetinglibrary.asco.org.

[SI-2017-6] "BeiGene (BGNE) Commences Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer".

[GP3-7] LTD, BeiGene (2 January 2018). "BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular Carcinoma". GlobeNewswire News Room.

[8] "Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.

[9] "Immunotherapy Trial's Early Results Show Activity in Solid Tumors". 26 July 2016.

[10] "Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Patients With NSCLC - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.